
Drug news
Roche halts development of RG 1658 for Dyslipidaemia
Roche has halted development of RG 1658 (dalcetrapib) due to its lack of efficacy in treating Dyslipidaemia. This decision is based on results from OUTCOMES, a trial that has been halted after RG 1658 failed to show any benefit for patients already experienced symptoms of coronary artery obstruction taking the drug plus existing standard of care, though there were no reported safety issues. The decision to terminate OUTCOMES was based on the recommendation of the independent Data and Safety Monitoring Board. Roche was planning to file for regulatory approval in the US in 2013. All studies in another development program, called HEART, have also been terminated.